X hits on this document

510 views

0 shares

0 downloads

0 comments

141 / 170

11

and the Sponsor, I mean everyone has done a great job analyzing the data we have. I

12

think that one of the challenges I am having is; we actually have examples of multiple

13

trials where there have been 40 events in a trial. That when the trial has been repeated

14

with more events not only has a beneficial effect been shown, but it’s been overwhelmed.

15

So, all right, so I’ll have to wait for that later.

2

MACE. The custom MACE was similar to the Prime MACE. I think you learn as you

3

go. I think the discussion about creatinine kinase levels, you know, has emerged and,

4

you know, I guess I share others concern that is extraordinarily nonspecific. I think going

5

forward, you know, you might want to reconstruct it without that. You know, I think

6

you’re going to be left with the problem of, do you have enough events to count and

7

that’s a problem I guess that you can’t solve by putting in a completely nonspecific

8

element to it. So I mean I think you guys did a pretty good job.

20

inclusion of other kinds of events that indicate an ischemic event like, need for

21

revascularization, you know, unstable angina like events that I guess might not be

22

captured in the custom MACE one, that I think would be another direction that I would

23

say might be very fruitful in looking for a meaningful broader event category.

9

DR. BURMAN: Thank you. Are there other comments? John?

10

DR. TEERLINK: So I would just want to second that the FDA has done,

16

DR. BURMAN: Are there any other comments?

17

DR. KONSTAM: I have one thing.

18

DR. BURMAN: Of course.

19

DR. KONSTAM: I think the other that’s come up is the potential for

1

DR. KONSTAM: I am sorry the custom. I didn’t mean the SMQ

140

24

DR. BURMAN: Thank you. Mike.

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

Document info
Document views510
Page views510
Page last viewedFri Dec 09 06:43:34 UTC 2016
Pages170
Paragraphs7975
Words54271

Comments